Bile Acid–Immune Signaling in the Gut: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Bile acids, traditionally recognized for their role in lipid absorption, are now established as potent regulators of gut immune signaling. Recent advances have illuminated complex interactions between bile acids and the intestinal immune system, influencing disease susceptibility and therapeutic responses. This review synthesizes the latest evidence on bile acid–immune crosstalk, emphasizing its clinical relevance in gastrointestinal and systemic diseases, underlying mechanisms, and implications for novel therapeutic strategies targeting bile acid pathways.

Introduction

The gut is a dynamic interface where host and microbial factors converge, orchestrating immune tolerance and defense. Bile acids, once considered mere digestive detergents, are increasingly recognized as signaling molecules influencing both innate and adaptive immunity. Their interaction with nuclear and membrane-bound receptors impacts immune cell differentiation, cytokine production, and epithelial barrier function. Understanding these mechanisms provides a foundation for innovative therapies in inflammatory, metabolic, and neoplastic disorders.

Epidemiology / Disease Burden

Dysregulation of bile acid metabolism and signaling contributes to the pathogenesis of various gastrointestinal disorders, including inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer. Epidemiological studies indicate rising incidence of these conditions globally, with an estimated prevalence of IBD over 6.8 million cases worldwide. Altered bile acid profiles have also been linked to metabolic syndrome, obesity, and nonalcoholic fatty liver disease (NAFLD), amplifying the burden of chronic disease and healthcare costs.

Pathophysiology

Bile acids are synthesized in the liver from cholesterol and undergo extensive enterohepatic circulation. In the gut, primary bile acids are converted to secondary bile acids by microbiota, modulating their signaling properties. Bile acids interact with receptors such as farnesoid X receptor (FXR), Takeda G protein-coupled receptor 5 (TGR5), and vitamin D receptor (VDR), among others. These receptors influence gene expression related to inflammation, immune cell trafficking, and epithelial integrity. Aberrant bile acid signaling can disrupt mucosal immunity, promote dysbiosis, and trigger chronic inflammation, underlying the pathogenesis of IBD and other disorders.

Risk Factors

Several factors predispose individuals to bile acid–mediated immune dysregulation. Genetic polymorphisms affecting bile acid synthesis and transporters, alterations in gut microbiota composition (dysbiosis), dietary patterns high in fat or low in fiber, and chronic liver diseases are notable contributors. Use of antibiotics or medications influencing bile acid metabolism (e.g., statins, bile acid sequestrants) may alter the gut bile acid pool and immune response. These risk factors interact in a multifactorial manner, shaping individual susceptibility and disease trajectory.

Clinical Features

Clinical manifestations of bile acid–immune signaling dysregulation vary with the underlying disease. In IBD, patients may present with diarrhea, abdominal pain, and extraintestinal symptoms, often correlating with altered fecal bile acid concentrations. PSC is characterized by cholestasis, pruritus, and progressive liver dysfunction, often associated with concurrent IBD. Bile acid diarrhea manifests as chronic watery stools due to impaired reabsorption or excess synthesis. Systemic effects may include metabolic disturbances and increased risk for malignancy in chronic disease states.

Diagnosis

Diagnosis relies on a combination of clinical evaluation, laboratory markers, imaging, and specialized assays. Serum and fecal bile acid profiling through liquid chromatography–mass spectrometry provides insights into bile acid composition and metabolism. Biomarkers such as fibroblast growth factor 19 (FGF19) reflect FXR activity and enterohepatic feedback. Imaging modalities, including MR cholangiopancreatography and elastography, aid in assessing structural and functional changes in the liver and biliary tree. Emerging omics technologies enable deeper characterization of bile acid–microbiota–immune interactions.

Treatment & Management

Therapeutic strategies target restoration of bile acid homeostasis and modulation of aberrant immune responses. Bile acid sequestrants (e.g., cholestyramine) alleviate symptoms in bile acid diarrhea by binding luminal bile acids. Ursodeoxycholic acid is used in cholestatic liver disease and may exert immunomodulatory effects. In IBD, biologic agents targeting cytokines and integrins are standard; however, interventions targeting bile acid signaling (e.g., FXR agonists) are gaining traction. Diet modification and microbiota-directed therapies (e.g., probiotics, fecal microbiota transplantation) modulate bile acid pools and immune tone.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of targeted therapies modulating bile acid receptors. FXR agonists (e.g., obeticholic acid) show promise in NAFLD, PSC, and certain IBD phenotypes by reducing inflammation and fibrosis. TGR5 agonists, still in early-phase studies, may enhance mucosal defense and metabolic regulation. Microbiome engineering and designer probiotics capable of modulating bile acid metabolism represent a frontier in personalized gut immunotherapy. Clinical trials are ongoing to elucidate efficacy, safety, and long-term outcomes of these novel agents.

Guideline Recommendations

Current clinical guidelines emphasize the importance of recognizing and managing bile acid dysregulation in gastrointestinal and hepatobiliary disorders. For suspected bile acid diarrhea, guidelines recommend SeHCAT (tauroselcholic acid) retention testing where available, or empirical therapeutic trials. In cholestatic liver disease, ursodeoxycholic acid remains first-line, with FXR agonists reserved for refractory cases. Multidisciplinary management, including dietetics and hepatology input, is advised for complex cases. Ongoing guideline updates are anticipated as evidence accumulates for emerging therapies targeting bile acid–immune pathways.

Conclusion

Bile acid–immune signaling in the gut represents a dynamic nexus of host–microbial interactions with profound implications for gastrointestinal and systemic health. Advances in mechanistic understanding have catalyzed the development of innovative, mechanism-based therapies for a spectrum of diseases. Integration of bile acid profiling, molecular diagnostics, and targeted interventions is poised to transform patient care. Continued research and guideline refinement will enable optimal translation of these insights into clinical practice, enhancing outcomes for patients with bile acid–related disorders.